Brokerages expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to announce ($0.24) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have made estimates for BioMarin Pharmaceutical’s earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.12). BioMarin Pharmaceutical reported earnings per share of ($0.53) in the same quarter last year, which suggests a positive year-over-year growth rate of 54.7%. The business is scheduled to announce its next quarterly earnings results on Thursday, February 22nd.

On average, analysts expect that BioMarin Pharmaceutical will report full-year earnings of ($0.64) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.50). For the next year, analysts anticipate that the company will report earnings of ($0.29) per share, with EPS estimates ranging from ($1.00) to $0.34. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $334.18 million during the quarter, compared to the consensus estimate of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The business’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.02 EPS.

Several brokerages recently issued reports on BMRN. Jefferies Group reiterated a “buy” rating and issued a $116.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, September 26th. Piper Jaffray Companies reiterated a “buy” rating and issued a $113.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, September 21st. Goldman Sachs Group reiterated a “buy” rating and issued a $129.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, October 6th. Stifel Nicolaus lowered their price target on BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating for the company in a report on Friday, October 27th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $117.00 price target on shares of BioMarin Pharmaceutical in a report on Friday, October 20th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $112.14.

In other news, insider Henry J. Fuchs sold 15,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $89.23, for a total transaction of $1,338,450.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP George Eric Davis sold 1,200 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $85.64, for a total transaction of $102,768.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,750 shares of company stock valued at $5,439,788. 1.85% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its position in shares of BioMarin Pharmaceutical by 1.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,126 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 54 shares during the last quarter. Comerica Bank lifted its position in shares of BioMarin Pharmaceutical by 1.0% during the second quarter. Comerica Bank now owns 7,358 shares of the biotechnology company’s stock worth $662,000 after purchasing an additional 76 shares during the last quarter. Fiera Capital Corp lifted its position in shares of BioMarin Pharmaceutical by 1.6% during the second quarter. Fiera Capital Corp now owns 6,613 shares of the biotechnology company’s stock worth $601,000 after purchasing an additional 101 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of BioMarin Pharmaceutical by 12.9% during the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 243 shares during the last quarter. Finally, ETRADE Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical by 7.1% during the second quarter. ETRADE Capital Management LLC now owns 4,528 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 300 shares during the last quarter. 99.15% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical (NASDAQ:BMRN) traded up $0.24 during mid-day trading on Tuesday, hitting $90.22. The stock had a trading volume of 874,400 shares, compared to its average volume of 1,288,222. The firm has a market cap of $16,010.00, a P/E ratio of -108.70 and a beta of 1.81. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical has a 1-year low of $80.10 and a 1-year high of $100.51.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/16/zacks-analysts-expect-biomarin-pharmaceutical-inc-bmrn-to-announce-0-24-eps.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.